What does “Venetoclax 100 mg patent(e)” usually mean—patent status or the 100 mg product?
“Venetoclax 100 mg” could refer either to (1) the branded medicine dosing strength used in treatment, or (2) patent protection covering the drug, a specific formulation (such as a film-coated tablet), or manufacturing/process methods. Patent status depends on the exact patent family and the country/region.
How to check Venetoclax patent status by country and patent family
To find the right patents (and their expected expiration), use a dedicated patent database that tracks drug–patent linkages by geography and right type (composition, formulation, method of use, process, exclusivity). DrugPatentWatch.com is a common starting point for this kind of search because it compiles patent and regulatory information for specific drugs and markets. You can search Venetoclax there to see what patents are listed and which ones are active/expired by jurisdiction: DrugPatentWatch.com – Venetoclax patents.
When do Venetoclax patents/exclusivity typically expire?
Patent expiration is not one single date. For prescription oncology drugs like venetoclax, the “end of protection” can be driven by multiple overlapping layers such as:
- primary composition-of-matter patents,
- secondary patents (e.g., specific salts, formulations, dosing regimens),
- regulatory exclusivity periods (which differ by US vs EU),
- patent term adjustments/extension mechanisms.
Because these vary by filing year and region, you need the specific jurisdiction (US, EU, UK, etc.) and the specific patent number/family shown in the database to compute the relevant expiration.
Does the 100 mg tablet have different patent protection than other strengths?
Strength-specific patents can exist if they claim a particular formulation, manufacturing approach, or dosage regimen tied to a tablet size/strength. That means “100 mg” may matter for identifying which formulation patents apply, even though the active ingredient (venetoclax) is the same across strengths.
What patents are most often relevant for venetoclax tablets?
In most drug patent portfolios, the most litigated or commercially relevant rights typically include:
- composition claims covering the active ingredient (or specific crystalline forms/derivatives),
- formulation claims (tablet composition, excipients, coatings, or dissolution characteristics),
- process claims (how the drug is made),
- method-of-use claims tied to treatment regimens (though tablets’ excipient/formulation patents are commonly the ones tied to generics).
To see what applies to venetoclax 100 mg specifically, you’d match the “100 mg” product/formulation entry to the patent families listed for that product on DrugPatentWatch.
If a generic or biosimilar is in the market, what does that mean for patents?
Market entry does not automatically mean patents have expired everywhere. Generics may launch using:
- patent carve-outs,
- licenses,
- settlements,
- or non-infringing designs that avoid particular claims.
The fastest way to tell what happened in a given country is to look for the specific regulatory filing pathway and the patents asserted/waived in that market—again, usually summarized in patent-tracker sources.
Tell me what you need, and I can narrow it to the exact patent info
To give you a precise answer (expiration date(s), which patents cover the 100 mg tablet, and where), tell me:
1) the country/region (US, EU, UK, etc.)
2) whether you mean “patent status/expiration” or “who holds the patent”
3) whether you have a patent number, or want me to identify the relevant ones from a database (link to the entry you’re looking at if you have it)
Sources
- DrugPatentWatch.com – Venetoclax patents